Renal Cancer - Results from #40

Papillary renal cell carcinoma revisited: impact of the World Health Organization 2022 classification on prognostication. November 27, 2024

French AFU Cancer Committee Guidelines - Update 2024-2026: Management of kidney cancer. November 26, 2024

Synchronized autologous T-cell immunotherapy with hyperthermia to previously heavy treated advanced renal cell carcinoma. November 26, 2024

Association between the systemic inflammation response index and kidney stones in US adults: a cross-sectional study based on NHANES 2007-2018. November 26, 2024

CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond. November 25, 2024

Risk factors for kidney cancer and socio-occupational category: significant impact of chlorinated solvents (UroCCR 111). November 25, 2024

Robot-assisted partial nephrectomy vs. percutaneous cryoablation for T1a renal tumors: a single-center retrospective analysis of outcomes and costs. November 25, 2024

Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. November 22, 2024

Tivozanib Monotherapy in the Frontline Setting for Patients with Metastatic Renal Cell Carcinoma and Favorable Prognosis. November 22, 2024

The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis. November 21, 2024

Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors. November 21, 2024

Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature. November 20, 2024

Longitudinal Trends of Comorbidities and Survival Among Kidney Cancer Patients in Asian Population. November 20, 2024

Associations of physical activity and sedentary time with health-related quality of life in patients with localized renal cell cancer: a cross-sectional analysis within the ReLife study. November 19, 2024

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report. November 19, 2024

Systemic therapy for non-clear cell renal cell carcinomas: A systematic review. November 18, 2024

Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram. November 18, 2024

Primary tumor ablation in metastatic renal cell carcinoma. November 15, 2024

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors. November 15, 2024

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma. November 14, 2024

Page 3 of 456